DC-based immunotherapy to treat Malignant Mesothelioma

Project Information

H2020MM04

Grant agreement ID: 668769

DOI 10.3030/668769

Project closed

EC signature date 1 December 2015

Start date 1 January 2016

End date 31 December 2021

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 5 782 965,00

EU contribution € 5 782 965,00

Coordinated by

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Author(s): Robert A. Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A. Fennell, Jan P. van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G. J. V. Aerts
Published in: Translational Lung Cancer Research, Issue 8/3, 2019, Page(s) 280-285, ISSN 2218-6751
Publisher: AME publishing company
DOI: 10.21037/tlcr.2019.05.05

Intellectual Property Rights

Patent (2)

METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS

Application/Publication number: EP 13821476
Date: 2013-12-20
Applicant(s): AMPHERA BV

Pharmaceutical composition for use in the treatment of cancer

Application/Publication number: PCT/NL2017/ 050809
Date: 2016-12-02
Applicant(s): AMPHERA BV